. 2017 Feb 19;8(14):23130–23141. doi: 10.18632/oncotarget.15506

Table 1. Clinical and demographic information and CTCs inspection in cases and healthy controls.

Cohorts	Cases or healthy controls	Gender	Age	Side	lobe	Tumor Size (cm)	TNM staging^Φ	Pathology	Status	Follow-up duration^# (month)	CTCs count prior to operation
Cohorts	Cases or healthy controls	Gender	Age	Side	lobe	Tumor Size (cm)	TNM staging^Φ	Pathology	Status	Follow-up duration^# (month)	E	M	E&M	Total
A (n = 18)	Case A1	Female	46	R	M	2	T1aN0M0	IA	DFS	7	0	0	8	8
	Case A2	Male	51	R	M	3	T1bN0M0	LPA	DFS	6	0	14	3	17
	Case A3	Female	59	L	U	3.5	T2aN0M0	IA	Recurrence	6	0	1	2	3
	Case A4	Female	60	R	U	2	T1aN0M0	IA	DFS	7	0	0	9	9
	Case A5	Female	52	L	U	2.5	T1bN0M0	IA	DFS	11	0	0	1	1
	Case A6	Female	53	R	L	0.8	T1aN0M0	AIS	DFS	7	1	1	3	5
	Case A7	Male	64	L	U	1.5	T1aN0M0	PDA	DFS	6	1	0	2	3
	Case A8	Female	41	R	U	2	T1aN0M0	IA	Recurrence	12	0	0	2	2
	Case A9	Female	73	R	U	3	T1bN0M0	IA	DFS	5	0	0	2	2
	Case A10	Female	43	R	L	2	T1aN0M0	IA	DFS	5	0	11	3	14
	Case A11	Female	60	R	L	3.3	T2aN0M0	IA	DFS	5	0	0	2	2
	Case A12	Female	70	R	U	2.2	T1bN0M0	IA	DFS	5	1	4	0	5
	Case A13	Male	50	R	M	2.5	T1bN0M0	IA	DFS	11	1	1	0	2
	Case A14	Male	60	L	L	3.5	T2aN0M0	IA	DFS	10	0	6	4	10
	Case A15	Male	71	R	M	1.9	T1aN0M0	MDA	DFS	10	0	1	4	5
	Case A16	Female	62	R	U	3	T1bN0M0	IA	DFS	9	0	0	0	0
	Case A17	Male	62	R	L	2	T1aN0M0	IA	Death^∮	10	1	2	0	3
	Case A18	Female	63	R	U	5	T2aN0M0	IA	DFS	12	0	8	10	18
B (n = 19)	Case B1	Male	61	R	L	5	T2aN0M0	PDA	Bone metastasis	20	N.A.
	Case B2	Male	52	R	M	4	T2aN0M0	IA	Recurrence	20	N.A.
	Case B3	Male	56	R	U	3.2	T2aN0M0	IA	Recurrence	12	N.A.
	Case B4	Female	60	L	U	3	T1bN0M0	IA	Recurrence	20	N.A.
	Case B5	Male	56	L	L	3	T1bN0M0	IA	Hepatic metastasis	60	N.A.
	Case B6	Female	63	L	U	2	T1aN0M0	IA	DFS	36	N.A.
	Case B7	Female	59	R	U	1.8	T1aN0M0	IA	DFS	12	N.A.
	Case B8	Female	52	R	U	3	T1bN0M0	IA	DFS	24	N.A.
	Case B9	Female	49	L	U	3	T1bN0M0	IA	DFS	18	N.A.
	Case B10	Female	47	L	U	2.5	T1aN0M0	IA	DFS	24	N.A.
	Case B11	Male	49	R	L	3	T1bN0M0	IA	DFS	12	N.A.
	Case B12	Female	49	R	U	3	T1bN0M0	IA	DFS	18	N.A.
	Case B13	Male	53	R	U	2	T1aN0M0	IA	DFS	36	N.A.
	Case B14	Female	56	R	L	2.5	T1bN0M0	IA	DFS	27	N.A.
	Case B15	Male	63	R	L	2	T1aN0M0	IA	DFS	12	N.A.
	Case B16	Male	60	L	U	0.8	T1aN0M0	AIS	DFS	24	N.A.
	Case B17	Female	51	R	L	2.5	T1bN0M0	IA	DFS	15	N.A.
	Case B18	Male	59	L	U	2.8	T1bN0M0	IA	DFS	20	N.A.
	Case B19	Male	55	R	M	3.5	T2aN0M0	IA	DFS	36	N.A.
C (n = 5)	Case C1	Female	77	L	L	3.5	T2aN0M0	IA	DFS	1	1	0	6	7
	Case C2	Male	69	R	U	1.5	T1aN0M0	IA	DFS	1	4	0	2	6
	Case C3	Female	62	R	L	3.1	T2aN0M0	IA	DFS	1	2	0	1	3
	Case C4	Female	64	L	U	2.3	T1bN0M0	MDA	DFS	1	0	0	3	3
	Case C5	Male	68	R	M	2.1	tuberculoma		DFS	1	0	2	3	5
D (n = 3)	Case D1	Male	64	L	L	6	T2bN0M0^Δ	LCNC	DFS	6	1	5	8	14
	Case D2	Male	62	R	U	2.5	T1bN0M0	IA	DFS	6	4	0	2	6
	Case D3	Female	45	R	M	3.5	T2aN0M0^Δ	IA	DFS	9	0	3	12	15
Healthy controls (n = 20)		7 Males 13 females	29.85 (mean age)	N.A.	N.A.	N.A.		N.A.	N.A.	N.A.	0*	0*	0*	0*

Note: IA: invasive adenocarcinoma; DFS: Disease free survival; LPA: lepidic predominant adenocarcinma; LCNC: Large cell neuroendocrine carcinoma;

AIS: adenocarcinoma in situ; PDA: poorly-differentiated adenocarcinoma; MDA: moderate-differentiated adenocarcinoma. N.A.: Not Available.

*: We did not find any CTC in 20 healthy controls.

#: Duration from diagnosis to last follow-up or confirmed tumor progression.

Ф: Die of pneumonia

Δ: Visceral pleural invasion

φ:Tumors were staged according to the American Joint Committee on Cancer 2010 Cancer Staging Manual